title: Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients.
abstract: Everolimus allows calcineurin-inhibitor reduction without loss of efficacy and may improve renal-transplant outcomes. In a 24-month, open-label study, 833 de novo renal-transplant recipients were randomized to everolimus 1.5 or 3.0 mg/day (target troughs 3-8 and 6-12 ng/mL, respectively) with reduced-exposure CsA, or mycophenolic acid (MPA) 1.44 g/day plus standard-exposure CsA. Patients received basiliximab +/- corticosteroids. The primary endpoint was composite efficacy failure (treated biopsy-proven acute rejection, graft loss, death or loss to follow-up) and the main safety endpoint was renal function (estimated glomerular filtration rate [eGFR], by Modification of Diet in Renal Disease [MDRD]) at Month 12 (last-observation-carried-forward analyses). Month 12 efficacy failure rates were noninferior in the everolimus 1.5 mg (25.3%) and 3.0 mg (21.9%) versus MPA (24.2%) groups. Mean eGFR at Month 12 was noninferior in the everolimus groups versus the MPA group (54.6 and 51.3 vs 52.2 mL/min/1.73 m(2) in the everolimus 1.5 mg, 3.0 mg and MPA groups, respectively; 95% confidence intervals for everolimus 1.5 mg and 3.0 mg vs MPA: -1.7, 6.4 and -5.0, 3.2, respectively). The overall incidence of adverse events was comparable between groups. The use of everolimus with progressive reduction in CsA exposure, up to 60% at 1 year, resulted in similar efficacy and renal function compared with standard-exposure CsA plus MPA.
authors.affiliation: Hospital do Rim e Hipertensão, São Paulo, Brazil. heliotedesco@hrim.com.br
authors.forename: H
authors.initials: H
authors.lastname: Tedesco Silva
authors.forename: D
authors.initials: D
authors.lastname: Cibrik
authors.forename: T
authors.initials: T
authors.lastname: Johnston
authors.forename: E
authors.initials: E
authors.lastname: Lackova
authors.forename: K
authors.initials: K
authors.lastname: Mange
authors.forename: C
authors.initials: C
authors.lastname: Panis
authors.forename: R
authors.initials: R
authors.lastname: Walker
authors.forename: Z
authors.initials: Z
authors.lastname: Wang
authors.forename: G
authors.initials: G
authors.lastname: Zibari
authors.forename: Y S
authors.initials: YS
authors.lastname: Kim
mesh_terms: D000305:Adrenal Cortex Hormones; D000328:Adult; D000911:Antibodies, Monoclonal; D000077552:Basiliximab; D001706:Biopsy; D004791:Enzyme Inhibitors; D000068338:Everolimus; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D007668:Kidney / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D007677:Kidney Function Tests; D016030:Kidney Transplantation / Q000009:adverse effects / Q000379:methods*; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000008:administration & dosage* / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins; D012449:Safety; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D004791:Enzyme Inhibitors; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab; D000068338:Everolimus; D009173:Mycophenolic Acid; D020123:Sirolimus